The importance of tau phosphorylation for neurodegenerative diseases.
Noble W, Hanger DP, Miller CC, Lovestone S. · 2013
Read The importance of tau phosphorylation for neurodegenerative diseases. by Noble W, Hanger DP, Miller CC, Lovestone S. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3696910.txt.
Introduction
Noble and colleagues review why abnormal tagging of the tau protein with phosphate groups matters in Alzheimer's disease and related dementias. Tangles of heavily tagged tau are a hallmark of these diseases. Yet evidence increasingly suggests the tangles themselves may not kill neurons; changes in soluble tau beforehand may do the damage.
This tagging alters tau's shape, location, and jobs. Those jobs extend beyond steadying microtubules to protecting DNA and supporting synapses. Tau pathology also appears to spread between connected neurons. Because enzymes drive the tagging, the reviewers discuss whether adjusting it is a realistic treatment lever for these diseases.
Catalog record
| CREATOR | Noble W, Hanger DP, Miller CC, Lovestone S. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Importance of Tau Phosphorylation for Neurodegenerative Diseases By Wendy Noble, Diane P. Hanger, Christopher C. J. Miller, Simon Lovestone Published in: Frontiers in Neurology DOI: 10.3389/fneur.2013.00083 ABSTRACT Fibrillar deposits of highly phosphorylated tau are a key pathological feature of several neurodegenerative tauopathies including Alzheimer’s disease (AD) and some frontotemporal dementias. Increasing evidence suggests that the presence of these end-stage neurofibrillary lesions do not cause neuronal loss, but rather that alterations to soluble tau proteins induce neurodegeneration. In particular, aberrant tau phosphorylation is acknowledged to be a key disease process, influencing tau structure, distribution, and function in neurons. Although typically described as a cytosolic protein that associates with microtubules and regulates axonal transport, several additional functions of tau have recently been demonstrated, including roles in DNA stabilization, and synaptic function. Most recently, studies examining the trans-synaptic spread of tau pathology in disease models have suggested a potential role for extracellular tau in cell signaling pathways intrinsic to neurodegeneration. Here we review the evidence showing that tau phosphorylation plays a key role in neurodegenerative tauopathies. We also comment on the tractability of altering phosphorylation-dependent tau functions for therapeutic intervention in AD and related disorders. INTRODUCTION Characteristic accumulations of highly phosphorylated tau protein aggregates are found in several neurodegenerative tauopathies including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and some forms of frontotemporal lobar dementia (FTLD-tau). It was assumed that these pathological tau aggregates are the toxic form of tau. However, recent studies indicate that soluble and highly phosphorylated tau species are more closely associated with synaptic dysfunction and cell loss (1–4). Tau is normally a highly soluble protein found predominantly in neurons. A total of six different isoforms of tau are expressed in the adult human CNS via alternative splicing of the MAPT gene, which comprises 16 exons and is found on chromosome 17q21.3. Regulated inclusion of exons 2 and 3 gives rise to tau isoforms with 0, 1, or 2 N-terminal inserts, whereas exclusion or inclusion of exon 10 leads to expression of tau isoforms with three (3R) or four (4R) microtubule-binding repeats (Figure 1A). In normal human brain the ratio of 4R–3R tau is approximately one, whereas in many tauopathies, this ratio is altered; PSP, corticobasal degeneration (CBD), and argyrophilic grain disease all exhibit over-expression of 4R tau isoforms, whereas Pick’s disease is mainly characterized by tau inclusions rich in 3R tau isoforms (5–9). [Figure: The human tau gene and six protein isoforms. (A) The six isoforms of human CNS tau. Exons 2 and 3 (E2 and E3) encode two different inserts of 28 amino acids near the N-terminus of tau. Absence of E2 and E3 gives rise to 0N tau isoforms, whereas inclusion of E2 produces 1N and inclusion of both E2 and E3 results in 2N tau isoforms. M1–M4 represent the four imperfect-repeat microtubule-binding domains, M2 being encoded by exon 10. Lack of M2 results in the formation of 3R tau and M2 inclusion results in 4R tau isoforms. The proline-rich domain in the center of the tau polypeptide is indicated. Alternative-splicing produces tau isoforms of 352–441 amino acids, as indicated. (B) Positioning of phosphorylation sites on tau from Alzheimer brain. Approximately 45 phosphorylation sites have been identified, these are found predominantly in the proline-rich domain and the regions flanking the microtubule-binding domain.] Tau is a phosphorylated protein, containing 85 potential serine (S), threonine (T), and tyrosine (Y) phosphorylation sites. Many of the phosphorylated residues on tau are found in the proline-rich domain of tau, flanking the microtubule-binding domain (Figure 1B). Both the phosphorylation status and isoform expression of tau are developmentally regulated and both are important factors for cytoskeletal plasticity during embryogenesis and early development. In early developmental stages a single tau isoform, 0N3R, is expressed and tau phosphorylation is elevated relative to adult brain. In contrast, all six tau isoforms are present in normal mature human brain, and at this stage tau phosphorylation is relatively reduced (8, 10). Despite the significant heterogeneity that exists between and within the various tauopathies, the deposited tau in pathological lesions is invariably highly phosphorylated. Mass spectrometric analysis, combined with Edman sequencing and specific antibody reactivity, shows that approximately ten phosphorylation sites can be detected on soluble tau purified from normal brain (10). In contrast, when insoluble aggregated tau is extracted from tauopathy brain, at least 16 phosphorylated residues have been found in PSP (11–13), and approximately 45 different serine, threonine, and tyrosine phosphorylation sites, representing more than 50% of all phosphorylatable residues, have been found in AD brain (10, 14–17). A large number of different kinases and phosphatases have been shown to regulate tau phosphorylation, and an imbalance in tau kinase and phosphatase activity is believed to result in tau hyperphosphorylation in disease. Tau kinases include: The proline-directed kinases glycogen synthase kinase-3 (GSK-3) (18–22), cyclin-dependent kinase 5 (cdk5) (23–25), and 5′ adenosine monophosphate-activated protein kinase (AMPK) (26, 27).Non-proline-directed kinases, such as casein kinase 1 (CK1) (10), microtubule affinity-regulating kinases (MARKs) (28–30), cyclic AMP-dependent protein kinase A (PKA) (31, 32), and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK-1A) (33, 34).Tyrosine kinases including Fyn (35, 36), Abl (37, 38), and Syk (39). In addition, several phosphatases dephosphorylate tau, including protein phosphatase-1, -2A, and -5 (PP1, PP2A, and PP5) (reviewed by (40). Importantly, many of these enzymes have been implicated in pathways affected by amyloid-beta (Aβ) in models of AD (27, 41–43). It remains to be established if the overall phosphorylation state of tau or phosphorylation at specific residues is important in disease pathogenesis, as suggested by studies in flies (44). However, there is evidence that phosphorylation of individual residues on tau can significantly impact its function, and this is discussed below. THE RELATIONSHIP BETWEEN PHOSPHORYLATION AND TAU STRUCTURE In addition to abnormal phosphorylation, tau protein in neurodegenerative disease brain can be modified in a number of ways, including N- and C-terminal proteolytic cleavage, altered conformation, nitration, glycosylation, acetylation, glycation, ubiquitylation, O-GlcNAcylation, aggregation, and filament formation (45, 46). Much research has focused on elucidating the relationship between phosphorylation and the changes in tau structure that are common in neurodegenerative disease brain. Evidence from this research suggests that phosphorylation occurs either prior to, or at the same time as, these other post-translational modifications and before aggregation occurs. It remains to be seen whether this temporal precendence indicates a causative relationship. Proteolytic tau cleavage Tau is subject to proteolytic cleavage by caspase-3 at aspartate (D) residue 421 (47), and N-terminal cleavage by calpain-1 (48) and caspase-6 (49). The tau fragments that are generated have been detected in affected regions of human tauopathy brain (47, 50). Caspase-cleaved tau fragments show an increased propensity to aggregate, and these may form a seeding nidus that promotes the aggregation and fibrillization of full-length tau species (51). In contrast, cleavage of tau by calpain may partially inhibit tau aggregation (50). The temporal relationship between tau cleavage and phosphorylation is unclear, with data showing that phosphorylation of different tau residues precedes (52), follows (47), and inhibits (53) the proteolytic cleavage of tau by caspase-3. However, substantial evidence shows that caspase-3-cleaved tau species are particularly prone to phosphorylation in both primary neuronal cells (54) and human tauopathy brain (47), and that phosphorylated and caspase-3-cleaved tau species readily form aggregates